tag:blogger.com,1999:blog-7857054149675424609.post1185831644496198284..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: RNAi Therapeutics Highlighted in Roche Media Day PresentationDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7857054149675424609.post-42026633011620380332009-12-25T16:06:19.592+00:002009-12-25T16:06:19.592+00:00I believe you are right in that RNAi, after some o...I believe you are right in that RNAi, after some of the buzz it rightly generated, is going through a phase in its development where investors have been increasingly reminded of the realities of the lengthy drug development process in the absence of new blockbuster deals and disappointment around some of the first RNAi Therapeutics drug candidates. All this is probably normal for a new exciting Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-63397053324542384892009-12-21T20:14:47.836+00:002009-12-21T20:14:47.836+00:00Dirk
Do you see the year 2009 as the year reality...Dirk<br /><br />Do you see the year 2009 as the year reality set in for the RNAi space? I remember how the buzz of monoclonal antibodies fell off for a few years after initial excitement and high related share prices.<br /><br />Is RNAi that far off that institutional investors would rather wait for progress before committing to the space? Obvious to ne the leader ALNY has seen the glow come off Anonymousnoreply@blogger.com